Edward Chow

Assoc. Prof & Research Director, Pharmacology Dept, NUS; PI @ CSI_Singapore; Interest: Tomorrow's tech that improves cancer treatment today

[Anand D Jeyasekharan @adj_23]

Is #personalization of drug combinations possible/ feasible in cancer care? Check out our latest publication in @ScienceTM: https://t.co/rXZJCA9bhA. Fantastic collaboration with @echow310 and clinical/ scientific colleagues @NUSMedicine @SingHealthSG @csi_singapore 1/n

[Edward Chow @echow310]

Great work led by @ChesterLeeDrum

[ACS Nano @acsnano]

#Bioorthogonal catalysis: self-assembling, porous exoshells encapsulate and deliver an iron-containing reaction center for the treatment of #BreastCancer, by Chester Drum and co-workers

https://t.co/Y2yDPVshp9

[Anand D Jeyasekharan @adj_23]

Really chuffed to have our work accepted as an oral presentation at #ASH2021 https://t.co/TmlOYax45A
We report our clinical experience with #personalized combination treatments in relapsed #lymphoma - a fantastic collaboration with @echow310 and colleagues across Singapore.

[Anand D Jeyasekharan @adj_23]

Hilarious. Cambridge flashbacks @rsyf2?

[Edward Chow @echow310]

Super proud of our first publication of 2021! MYC synthetic lethality and how AI can improve synthetic lethal drug combination design.#Cancer #medicine #AI https://t.co/yXaF4jClq6

[CSI Singapore @csi_singapore]

DEADLINE EXTENDED! The closing date for abstract submission has been extended to 11 January 2021. Submit your abstracts today: https://t.co/djO9qffAcd

[CSI Singapore @csi_singapore]

Our bond free premium scholarship provides you with the opportunity to work with a dynamic team of renowned scientists in an intellectually stimulating environment. Apply for the CSI PhD Graduate Program now! https://t.co/EhapbVK9G6

[CSI Singapore @csi_singapore]

Do not miss the opportunity to present your research at the Epigenetics in Cancer Symposium 2021! Abstract submission closes on 28 December. Submit your abstract today! https://t.co/djO9qffAcd

[Dean Ho @thedeanh]

It was a privilege working with an amazing team on this paper @TrendsinBiotech! @WeAreWisDM @TheN1Institute @BME_NUS @chngwj @PersonalizedMed @The__Liver @echow310

[CSI Singapore @csi_singapore]

Abstract submission is now OPEN for the Epigenetics in Cancer Symposium 2021! Find out more here: https://t.co/AKF9EE8lVY Register today at: https://t.co/dIfAFwFNoX

[CSI Singapore @csi_singapore]

The Epigenetics in Cancer Symposium (15-17 Feb 2021) is a high profile conference with a lineup of internationally distinguished speakers. Registration is now open: https://t.co/9WHFeIKXsv More info available here: https://t.co/GEKKYI8Dhe @denniskappei @DefossezPierre

[The Lancet Oncology @TheLancetOncol]

ICYMI: The NADIM study: #Neoadjuvant #chemotherapy and #nivolumab in resectable non-small-cell #lungcancer: an open-label, multicentre, single-arm, phase 2 trial
#NSCLC #lcsm https://t.co/ujqEpEHbx4

[Samir Mitragotri @SMitragotri]

Check out our recent paper in Adv. Mat. on non-genetic modifications of cells by depositing nano-complexes of biomomecules on cell surfaces. Anti-PDL1 nano-complexes on macrophages markedly improved tumor response in mice https://t.co/4bPjlJ1yKV @wyssinstitute @hseas

[AACR @AACR]

Free registration is open for the virtual @CSI_Singapore Frontiers in Cancer Science Annual Conference, Nov 2-6. We are partnering with FCS to organize three AACR-FCS Education Sessions for graduate students and early-career investigators. Learn more:
https://t.co/QCCUh7Q0tf

[Edward Chow @echow310]

Good things happen when engineering principles are applied to cancer research and drug development. Enjoyed this review by @khademh about AI/Engineering applied towards IO. #ArtificialIntelligence #oncology #Immunotherapy https://t.co/YYvOvQO4Fm

[Edward Chow @echow310]

A recent review in our SLAS Technology comprehensively covers how AI is applied at every step of drug development, from target identification to patient stratification. #ArtificialIntelligence #Pharmaceutical #PrecisionMedicine #SLAS

https://t.co/u8n7Mnn7zh